twistedneck said:
Anybody know? Most endurance studies are done with Test and some DHT from test.. never exogeneous DHT. Will this crank up my hematocrit?
I believe it will increase endurance to some degree, as athletes who are tested at each event use it for doping, as it is not easily detectable......
5 Alpha-dihydrotestosterone
5 Alpha-dihydrotestosterone (DHT) is the principal active metabolite of testosterone and has a greater binding affinity to the androgen receptor than testosterone. It transforms more readily to the steroid receptor complex and dissociates from this complex more slowly than does testosterone. It is used to enhance performance in a variety of sports.
DHT has been a licensed pharmaceutical in some countries and gained considerable prominence when 11 Chinese swimmers were found to have taken the drug in the 1994 Asian Games in Tokyo. There are no published data showing there is any effect on sporting performance.
Dose: Probably greater than 25 mg twice daily, percutaneously.
IOC status: Banned.
Adverse reactions: While there are few data, it is reasonable to expect that typical androgenic adverse effects such as baldness in males, hirsutism in females and acne will occur.
Detection: DHT does not alter the T/E ratio, but it can be detected by determining the ratios of other steroids to epitestosterone and LH.9
It has shown to raise hemaglobin and hematocrit levels in elderly males taking DHT for replacement therapy as current evidence shows estrogen to be a more volatile culprit in BPH.
The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study.
Kunelius P, Lukkarinen O, Hannuksela ML, Itkonen O, Tapanainen JS.
Division of Urology, Department of Surgery, University of Oulu, FIN-90014 Oulu, Finland.
The objective of the study was to investigate the effects of dihydrotestosterone (DHT) gel on general well-being, sexual function, and the prostate in aging men. A total of 120 men participated in this randomized, placebo-controlled study (60 DHT and 60 placebo). All subjects had nocturnal penile tumescence once per week or less, andropause symptoms, and a serum T level of 15 nmol/liter or less and/or a serum SHBG level greater than 30 nmol/liter. The mean age was 58 yr (range, 50-70 yr). Of these subjects, 114 men completed the study. DHT was administered transdermally for 6 months, and the dose varied from 125-250 mg/d. General well-being symptoms and sexual function were evaluated using a questionnaire, and prostate symptoms were evaluated using the International Prostate Symptoms Score, transrectal ultrasonography, and assay of serum prostate-specific antigen. Early morning erections improved transiently in the DHT group at 3 months of treatment (P < 0.003), and the ability to maintain erection improved in the DHT group compared with the placebo group (P < 0.04). No significant changes were observed in general well-being between the placebo and the DHT group. Serum concentrations of LH, FSH, E2, T, and SHBG decreased significantly during DHT treatment. Treatment with DHT did not affect liver function or the lipid profile.
Hemoglobin concentrations increased from 146.0 +/- 8.2 to 154.8 +/- 11.4 g/liter, and hematocrit from 43.5 +/- 2.5% to 45.8 +/- 3.4% (P < 0.001). Prostate weight and prostate-specific antigen levels did not change during the treatment. No major adverse events were observed. Transdermal administration of DHT improves sexual function and may be a useful alternative for androgen replacement. As estrogens are thought to play a role in the pathogenesis of prostate hyperplasia, DHT may be beneficial, compared with aromatizing androgens, in the treatment of aging men.
DHT derivative stanozolol was a favourite for athletes like Ben Johnson, but this was mostly for increased explosiveness in the running event without the unwanted weight gain.
Although DHT can cause modest increases in hemaglobin and hematocrit levels, drugs like epo or aranesp(darbepoetin alfa) are much more effective.
B32